# US 2008/0188460 A1 · Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188460 A1
- Document ID: US20080188460A1
- Status: Published application
- Kind: A1
- Application number: 12/011,225
- Filed: 2008-01-24
- Published: 2008-08-07
- Earliest claimed: 2007-02-02
- Assignees: Les Laboratoires Servier
- Inventors: Patrick Casara; Thierry Le Diguarher; Olivier Geneste; John Hickman
- Web page: https://patentgrep.com/patent/US20080188460A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I): wherein A represents a 5, 6 or 7-membered (hetero)aromatic or non-aromatic ring, n and n′ represent 0, 1 or 2 X represents an alkylene chain as defined in the description, R3 represents an aryl or heteroaryl group, one of the groups R1 and R2 represents a hydrogen atom and the other represents a group of formula (II) as defined in the description. Medicinal products containing the same which are useful in treating conditions involving a defect in apoptosis.

## Claims

### Claim 1

A compound selected from those of formula (I):
wherein
A represents a 5, 6 or 7-membered aromatic or non-aromatic ring having 1 or 2 hetero atoms selected from oxygen, sulphur and nitrogen, wherein the nitrogen atom may optionally be substituted by a linear or branched (C1-C6)alkyl group, it being understood that ring A cannot contain 2 sulphur atoms or 2 oxygen atoms and that one of the ring members may be a C═O group,
n and n′, which may be identical or different, represent 0, 1 or 2, where 0<n+n′<4,
R3 represents an aryl or heteroaryl group,
X represents a linear or branched alkylene chain having from 1 to 6 carbon atoms, wherein one or two of which carbon atoms may be replaced by an oxygen atom, a cycloalkylene group, an arylene group, a heteroarylene group or an SO2 group,
one of R1 and R2 represents a hydrogen atom and the other represents a group of formula (II):
wherein:
Y represents a C═O or CH2 group,
R5 represents a hydrogen atom and R6 represents a hydrogen atom or an —NR7R′7 or —CH2—NR7R′7 group wherein each of R7 and R′7, which may be identical or different, independently represents a hydrogen atom or a linear or branched (C1-C6)alkyl group substituted by one or more aryl, heteroaryl, aryloxy, heteroaryloxy, arylthio, heteroarylthio, heterocycloalkyl or —NR10R′10 groups wherein:
R10 and R′10, which may be identical or different, are selected from hydrogen, linear or branched (C1-C6)alkyl, linear or branched (C1-C6)alkoxy, aryl and heteroaryl, or
R10 and R′10 form a saturated or unsaturated cyclic or bicyclic group which may contain a hetero atom selected from oxygen, nitrogen and sulphur, it being understood that one or more of the ring members may represent a C═O group, and wherein the cyclic or bicyclic group may be optionally substituted by from 1 to 3 groups selected from linear or branched (C1-C6)alkyl optionally substituted by a hydroxy or amino group, linear or branched (C1-C6)alkoxy, hydroxy, carboxy, formyl, nitro, cyano, amino, linear or branched polyhalo-(C1-C6)alkyl, alkoxycarbonyl and halogen atoms,
or R5 and R6, together with the two carbon atoms carrying them, form an aromatic or non-aromatic ring having 5 or 6 ring members, one nitrogen atom of which being in the position para to the SO2 group, and which may contain in addition to the nitrogen atom a further nitrogen atom and/or an SO2 group, wherein the ring may be substituted by an R7 group as defined above,
R4 represents a halogen atom or an NO2, R8, SO2—R9, linear or branched (C1-C6)-alkyl or linear or branched (C1-C6)alkoxy group, wherein R8 a hydrogen atom or a linear or branched (C1-C6)alkyl group substituted by one or more aryl, heteroaryl, aryloxy, heteroaryloxy, arylthio, heteroarylthio, heterocycloalkyl or —NR10R′10,
R9 represents an amino group or a linear or branched (C1-C6)alkyl group optionally substituted by one or more halogen atoms,
it being understood that:
“aryl” means a phenyl, naphthyl or biphenyl group,
“heteroaryl” means a mono- or bi-cyclic group having at least one aromatic moiety and having from 5 to 10 ring members which may contain from 1 to 3 hetero atoms selected from oxygen, sulphur and nitrogen,
“heterocycloalkyl” means a mono- or bi-cyclic non-aromatic group having from 4 to 10 ring members which may contain from 1 to 3 hetero atoms selected from oxygen, sulphur and nitrogen,
“cycloalkyl” means a mono- or bi-cyclic non-aromatic group containing from 4 to 10 ring members,
wherein the aryl, heteroaryl, heterocycloalkyl and cycloalkyl may be optionally substituted by from 1 to 3 groups selected from linear or branched (C1-C6)alkyl optionally substituted by a hydroxy or amino group, linear or branched (C1-C6)alkoxy, hydroxy, carboxy, formyl, nitro, cyano, amino, linear or branched polyhalo-(C1-C6)alkyl, alkoxycarbonyl and halogen atoms, and
“arylene”, “heteroarylene” and “cycloalkylene” mean, respectively, a bivalent aryl, heteroaryl or cycloalkyl group as defined above,
its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Y represents a C═O group.

### Claim 3 (depends on 1)

The compound of claim 1, wherein n and n′ represent 1.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R4 represents a NO2 or SO2—CF3 group.

### Claim 5 (depends on 1)

The compound of claim 1, wherein X—R3 represents a ([1,1′-biphenyl]-2-yl)methyl group optionally substituted by one or more groups selected from halogen, cyano, amino, aminomethyl and trifluoromethyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R5 represents a hydrogen atom.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R7 represents 1-(N,N-dimethylamino)-4-(phenylsulphanyl)-butan-3-yl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R7 represents a 1-(NR10R′10)-4-(phenylsulphanyl)-butan-3-yl group, R10 and R′10 being such that they form a saturated or unsaturated cyclic or bicyclic group, optionally containing a hetero atom selected from oxygen, nitrogen and sulphur.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R′7 represents a hydrogen atom.

### Claim 10 (depends on 1)

The compound of claim 1 which is selected from:
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(dimethylamino)-1-[(phenyl-sulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(10aα)-2-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indol-8-yl}carbonyl)-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(10aβ)-2-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indol-8-yl}carbonyl)-4-({(1R)-3-(dimethylamino)-1-[(phenyl-sulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(10aα)-2-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indol-8-yl}carbonyl)-4-({(1R)-3-(4-morpholinyl)-1-[(phenyl-sulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(10aα)-2-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-1,2,3,4,10,10a-hexa-hydropyrazino[1,2-a]indol-8-yl}carbonyl)-4-({(1R)-3-(4-morpholinyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulphonyl]benzene-sulphonamide,
N-[((4aR)-3-{[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl}-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl)carbonyl]-4-({(1R)-3-(4-morpholinyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-[(trifluoromethyl)-sulphonyl]benzenesulphonamide,
N-[((10aβ)-2-{[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl}-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indol-8-yl)carbonyl]-4-({(1R)-3-(4-morpholinyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-[(trifluoromethyl)-sulphonyl]benzenesulphonamide,
N-[((4aR)-3-{[4-(4-chlorophenyl)-3-pyridyl]methyl}-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl)carbonyl]-4-({(1R)-2-(dimethylamino)-1-[(phenylsulphanyl)methyl]ethyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[(4-amino-4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzene-sulphonamide,
N-[((4aR)-3-{[4-(aminomethyl)-4′-chloro-[1,1′-biphenyl]-2-yl]methyl}-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl)carbonyl]-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzene-sulphonamide trihydrochloride,
N-[((4aR)-3-{[3′-fluoro-4′-chloro-[1,1′-biphenyl]-2-yl]methyl}-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl)carbonyl]-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzene-sulphonamide,
N-[((4aR)-3-{[4′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl]methyl}-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl)carbonyl]-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-[((4aR)-3-{[4′-cyano-[1,1′-biphenyl]-2-yl]methyl}-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl)carbonyl]-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[2-(1,3-benzodioxol-5-yl)benzyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(4-morpholinyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(4-morpholinyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulphonyl]-benzenesulphonamide,
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(4-methyl-1-piperazinyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(1-piperidyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(1-pyrrolidinyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(3,6-dihydro-1(2H)-pyridyl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-(1-azepanyl)-1-[(phenyl-sulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide,
N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}carbonyl)-4-({(1R)-3-((1R,5S)-3-azabicyclo-[3.1.0]hex-3-yl)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzene-sulphonamide,
and addition salts thereof with a pharmaceutically acceptable acid or base.

### Claim 11 (depends on 1)

The compound of claim 1 which is selected from N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}-carbonyl)-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide, and addition salts thereof with a pharmaceutically acceptable acid or base.

### Claim 12 (depends on 1)

The compound of claim 1 which is N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}-carbonyl)-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide bis(hydrochloride).

### Claim 13 (depends on 1)

The compound of claim 1 which is sodium N-({(4aR)-3-[(4′-chloro-[1,1′-biphenyl]-2-yl)methyl]-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinolin-8-yl}-carbonyl)-4-({(1R)-3-(dimethylamino)-1-[(phenylsulphanyl)methyl]propyl}amino)-3-nitrobenzenesulphonamide.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising as active ingredient a compound of claim 1, or an addition salt thereof with a pharmaceutically acceptable acid or base, in combination with one or more pharmaceutically acceptable excipients.

### Claim 15 (depends on 1)

A method of treating a living animal body, including a human, afflicted with a condition involving a defect in apoptosis, comprising the step of administering to the living animal body, including a human, an amount of a compound of claim 1 which is effective for treatment of the condition.

### Claim 16 (depends on 1)

A method of treating a living animal body, including a human, afflicted with cancer, comprising the step of administering to the living animal body, an amount of a compound of claim 1 which is effective for treatment of cancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancers of the colon, oesophagus and liver, lymphoblastic leukaemias, follicular lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancers, non-small-cell lung cancers, prostate cancers and small-cell lung cancers.

### Claim 18 (depends on 1)

A composition comprising a combination of a compound of claim 1 and an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors and kinase inhibitors.

### Claim 19 (depends on 18)

A method of treating a living animal body, including a human, afflicted with cancer, comprising the step of administering to the living animal body, including a human, an amount of a composition of claim 18 which is effective for treatment of cancer.

### Claim 20 (depends on 1)

A method of treating a living animal body, including a human, afflicted with cancer, comprising the step of adminstering to the living animal body, including a human, an amount of a compound of claim 1 which is effective for treatment of cancer in combination with radiotherapy.
